Prothena (PRTA)
(Delayed Data from NSDQ)
$20.81 USD
+0.60 (2.97%)
Updated May 31, 2024 04:00 PM ET
After-Market: $20.78 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 81 - 100 ( 331 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Prothena Prepping for an Acquisition: Our Thoughts; Reit Buy and Raising to PT $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Did you Know Prothena has an Anti-Abeta Antibody with Superior Binding Profile? Reit Buy and Raising PT $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Dynamic Pipeline Keeps its Focus on Protein Misfolding Diseases; Reit Buy and $33 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Implications of the SPARK trial data for Prasinezumab and Resurgence of Birtamimab Our Thoughts; PT up to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Return of the Birtamimab?Bolstering Prothena''s Rich Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Positive Data From Prothena?s Phase 1 Long-Term Extension Study of PRX004?Hope for ATTR-CM Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A